Brimblecombe, K.R. et al. (2023) Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine, co-varies with risk factors for Parkinson’s.
Stephanie J Cragg, Katherine Brimblecombe
Published: 2024-01-10 DOI: 10.17504/protocols.io.4r3l27dxxg1y/v3
Calb1
L-type calcium channel
Parkinson's disease
dopamine D2 receptor
dopamine release
dopamine transporter
sex differences
striatum
synuclein
Abstract
This collection contains five protocols detailing methods used in Brimblecombe, K.R. et al. (2023) Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine, co-varies with risk factors for Parkinson’s.
